Eisai, Merck, Pfizer join Accenture to build R&D cloud platform

October 10, 2014 | Friday | News | By BioSpectrum Bureau

Eisai, Merck, Pfizer join Accenture to build R&D cloud platform

(Photo Courtesy: www.zdnet.com)

(Photo Courtesy: www.zdnet.com)

Eisai, Merck, and Pfizer have joined forces to build a standards-driven platform powered by Oracle hardware and software to help pharmaceutical companies simplify and speed drug development.

Accenture Life Sciences cloud for R&D solution is a new IT platform offering a transformation of the R&D technology landscape.

"We have helped these companies successfully improve trial efficiencies, cut trial costs and enhance the productivity of trial participants," said Accenture in a note.

This cloud platform offers a forward-looking, transformation of the R&D technology landscape providing new ways to use data across the development lifecycle to bring life-enhancing products to patients faster.

The cloud brings together multiple internal and external data sources across clinical, safety, regulatory and operational functions into a single analytics platform, creating actionable insights to accelerate drug development and improve patient outcomes.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy